Matthew Rainwater
General Practice · Fresno, CANPI 1881044873
Payments from drug & device makers
Across 372 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$971
- Sumitomo Pharma America, Inc.$874
- Antares Pharma, Inc.$487
- Astellas Pharma US Inc$476
- Urovant Sciences Inc$418
- AbbVie$228
- plus $3K from 36 others
What the payments were for
- Food & beverage$6,32397%
- Education$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,495 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ElmironPentosan Polysulfate Sodium | 159 | $272,961 |
| MyrbetriqMirabegron | 125 | $108,370 |
| GemtesaVibegron | 73 | $75,427 |
| Tamsulosin Hcl | 1,471 | $33,407 |
| OrgovyxRelugolix | 13 | $33,327 |
| XyostedTestosterone Enanthate | 55 | $32,207 |
| Solifenacin Succinate | 277 | $25,174 |
| Abiraterone Acetate | 13 | $23,480 |
| Tolterodine Tartrate ErTolterodine Tartrate | 149 | $16,217 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 85 | $9,697 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,571 |
| Oxybutynin Chloride ErOxybutynin Chloride | 248 | $7,966 |
| Testosterone Cypionate | 146 | $7,855 |
| Finasteride | 289 | $4,254 |
| Dutasteride | 47 | $3,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $874 | $108,75486 claims |
| Astellas Pharma US IncMyrbetriq | $476 | $108,370125 claims |
| Antares Pharma, Inc.Xyosted | $487 | $32,20755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Fresno
- Ryan DunlopFresno$151K
- Hipolito MarianoFresno$133K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.